Beaumont Asset Management L.L.C. Sells 866 Shares of Becton, Dickinson and Company (NYSE:BDX)

Beaumont Asset Management L.L.C. lessened its stake in Becton, Dickinson and Company (NYSE:BDX) by 14.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,308 shares of the medical instruments supplier’s stock after selling 866 shares during the quarter. Becton, Dickinson and Company makes up about 0.9% of Beaumont Asset Management L.L.C.’s holdings, making the stock its 22nd largest position. Beaumont Asset Management L.L.C.’s holdings in Becton, Dickinson and Company were worth $1,294,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Ritholtz Wealth Management increased its position in Becton, Dickinson and Company by 13.8% in the third quarter. Ritholtz Wealth Management now owns 1,877 shares of the medical instruments supplier’s stock worth $485,000 after buying an additional 228 shares during the last quarter. Global Retirement Partners LLC lifted its stake in Becton, Dickinson and Company by 7.3% during the third quarter. Global Retirement Partners LLC now owns 2,061 shares of the medical instruments supplier’s stock worth $535,000 after purchasing an additional 140 shares during the last quarter. Naples Global Advisors LLC lifted its stake in Becton, Dickinson and Company by 45.7% during the third quarter. Naples Global Advisors LLC now owns 1,595 shares of the medical instruments supplier’s stock worth $412,000 after purchasing an additional 500 shares during the last quarter. Capital Investment Advisors LLC bought a new stake in Becton, Dickinson and Company during the third quarter worth about $482,000. Finally, Avior Wealth Management LLC lifted its stake in Becton, Dickinson and Company by 37.6% during the third quarter. Avior Wealth Management LLC now owns 3,934 shares of the medical instruments supplier’s stock worth $1,017,000 after purchasing an additional 1,076 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on BDX. Raymond James lifted their price target on Becton, Dickinson and Company from $269.00 to $275.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Barclays lifted their price target on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a research note on Monday, February 5th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $280.00.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares in the company, valued at approximately $542,348.04. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.2 %

Shares of NYSE:BDX traded up $0.48 during trading on Tuesday, hitting $234.36. The stock had a trading volume of 800,504 shares, compared to its average volume of 1,384,945. Becton, Dickinson and Company has a 12 month low of $229.40 and a 12 month high of $287.32. The company has a market capitalization of $67.71 billion, a PE ratio of 55.42, a PEG ratio of 1.93 and a beta of 0.43. The firm’s fifty day moving average is $239.81 and its 200 day moving average is $241.99. The company has a quick ratio of 0.64, a current ratio of 1.08 and a debt-to-equity ratio of 0.56.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, February 1st. The medical instruments supplier reported $2.68 EPS for the quarter, beating the consensus estimate of $2.39 by $0.29. Becton, Dickinson and Company had a return on equity of 13.57% and a net margin of 6.44%. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.73 billion. During the same period last year, the business posted $2.98 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Analysts anticipate that Becton, Dickinson and Company will post 12.94 EPS for the current fiscal year.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.